MCMedicalCodingSoftware
Free trial
XW0435A

XW0435A: Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Cefto Medocaril in Central Vein, Perc, New Tech 10

How XW0435A is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology: What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective: the verb of the procedure
  4. 4Body partThe specific site
  5. 3ApproachHow the site was reached
  6. 5DeviceWhat was left in place, if anything
  7. AQualifierA further distinction where one applies

Codes near XW0435A

In CMS’s own ordering, which groups codes that differ by only the last character or two, usually the approach, device or qualifier.

  • XW033WBIntroduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW04308Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0430BIntroduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW0431BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW0433AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW0434AIntroduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04357Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04358Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0435AIntroduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04368Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0436CIntroduction of Landiolol Antiarrhythmic into Central Vein, Percutaneous Approach, New Technology Group 12
  • XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
  • XW04378Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04388Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0438AIntroduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04396Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW04398Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
ICD-10-PCSFY2027